Team:Brown

From 2009.igem.org

(Difference between revisions)
 
(138 intermediate revisions not shown)
Line 1: Line 1:
-
<div style="background-color:black">
+
{{Brown}}
-
[[Image:Allergenebanner09.gif|960px]]
 
-
{| style="color:#1b2c8a;background-color:white;" cellpadding="3" cellspacing="1" border="0" bordercolor="#fff" width="62%" align="center"
 
-
!align="center"|[[Team:Brown|Home]]
 
-
!align="center"|[[Team:Brown/Team|The Team]]
 
-
!align="center"|[[Team:Brown/Project|The Project]]
 
-
!align="center"|[[Team:Brown/Parts|Parts Submitted to the Registry]]
 
-
!align="center"|[[Team:Brown/Notebook|Notebook]]
 
-
|}
 
-
<p>
+
 
-
{| style="color:#1b2c8a;background-color:white;" cellpadding="3" cellspacing="1" border="0" bordercolor="#fff" width="62%" align="left"
+
 
-
!align="left"| Every year, over fifty million people in the US suffer from allergic rhinitis, the most common type of allergy. The prevalence of allergic rhinitis and other and other inflammatory diseases has dramatically increased over the past two decades. Allergens, such as pollen, dust, and dander, cause the excessive release of histamine in the nasal cavity, resulting in nasal congestion, itching, burning, sneezing, and overall discomfort. Current treatments include over-the-counter antihistamines, however, side effects of these drugs include drowsiness, restlessness, and poor concentration. For patients suffering from chronic allergies and inflammation, there is a great need for an alternative strategy for combating allergic symptoms without causing significant side effects.The 2009 Brown University iGEM team worked to treat allergic rhinitis by engineering Staphylococcus epidermidis, a microbe endogenous to the human nasal flora, to secrete a recombinant histamine-binding protein in response to the elevated histamine concentrations of an allergic response. The engineered strain of S. epidermidis will function as a self-regulating drug factory in the nose, providing relief without any negative side effects |}
+
 
 +
[[Image:Brownbanner.gif|center|800px]]
 +
----
 +
 
 +
 
 +
Every year, over '''<big>fifty million people</big>''' in the US suffer from '''<big>allergic rhinitis</big>''',
 +
the most common type of allergy. Allergens such as pollen, dust, and dander result in nasal congestion, itching, burning, sneezing, and overall '''<big>discomfort</big>'''. Current treatments include over-the-counter '''<big>antihistamines</big>''', however, side effects of these drugs include drowsiness, restlessness, and poor concentration. For patients suffering from chronic allergies and inflammation, there is a great '''<big>need for an alternative strategy</big>''' for combating allergic symptoms '''<big>without</big>''' causing '''<big>significant side effects</big>'''.
 +
 
 +
 
 +
The '''<big>2009 Brown University iGEM</big>''' team worked to treat allergic rhinitis by '''<big>engineering Staphylococcus epidermidis</big>''', a microbe endogenous to the human nasal flora, to '''<big>secrete</big>''' a recombinant '''<big>histamine-binding protein</big>''' in response to the elevated histamine concentrations of an allergic response. The engineered strain of S. epidermidis will function as a '''<big>self-regulating drug factory in the nose</big>''', providing relief, '''<big>without</big>''' any negative '''<big>side effects</big>'''.
 +
 
 +
 
 +
----
 +
<html><head><META http-equiv="Content-Type" content="text/html; charset=utf-8"></head><body>
 +
<center>
 +
<div>
 +
<table width="827" border="5">
 +
 
 +
<font size="24">
 +
<tr>
 +
    <td width="165" height="107"><center><a href="https://2009.igem.org/Team:Brown/Team"><img src="https://static.igem.org/mediawiki/2009/8/8c/Teambutton.gif" width="168" height="100" align="absmiddle" longdesc="https://static.igem.org/mediawiki/2009/8/8c/Teambutton.gif"></td>
 +
 
 +
    <td width="164" height="107"><center><a href="https://2009.igem.org/Team:Brown/Parts"><img src="https://static.igem.org/mediawiki/2009/3/33/Partsbutton.gif" alt="" width="161" height="100" longdesc="https://static.igem.org/mediawiki/2009/3/33/Partsbutton.gif"></td>
 +
 
 +
      <td width="154" height="107"><center><a href="https://2009.igem.org/Team:Brown/Notebook_Weekly_Logs"><img src="https://static.igem.org/mediawiki/2009/c/ce/Notebookbutton.gif" width="157" height="100"></td>
 +
 +
<td width="154"><center><a href="https://2009.igem.org/Team:Brown/Project_Introduction"><img src="https://static.igem.org/mediawiki/2009/6/6e/Learnmoreallergiesbutton.gif" alt="" width="150" height="100" longdesc="https://static.igem.org/mediawiki/2009/6/6e/Learnmoreallergiesbutton.gif"></td>
 +
   
 +
<td width="156"><center><a href="https://2009.igem.org/Team:Brown/Project_Implications"><img src="https://static.igem.org/mediawiki/2009/9/97/Implicationsbutton.gif" alt="" width="157" height="100" longdesc="https://static.igem.org/mediawiki/2009/9/97/Implicationsbutton.gif"></td>
 +
  </tr>
 +
 
 +
  <tr>
 +
    <td colspan="2"><a href="https://2009.igem.org/Team:Brown/Project"><img src="https://static.igem.org/mediawiki/2009/2/2a/Projectabstractbutton.gif" width="335" height="100"></td>
 +
 
 +
    <td colspan="3">&nbsp;<i>Learn more about Allergene: a synthetically engineered, self-regulating drug factory in the &nbsp;nose.</i> </td>
 +
  </tr>
 +
  <tr>
 +
    <td colspan="2"><a href="https://2009.igem.org/Team:Brown/Project_Histamine_Sensor"><img src="https://static.igem.org/mediawiki/2009/d/d0/Histaminesensorbutton.gif" width="335" height="100"></td>
 +
    <td colspan="3">&nbsp;<i>When an allergic response occurs, our system senses a change in histamine levels above &nbsp;threshold and initiates an intracellular cascade, signaling cells to respond appropriately to &nbsp;the increase in histamine concentration.</i> </td>
 +
  </tr>
 +
  <tr>
 +
 
 +
  <tr>
 +
    <td colspan="2"><a href="https://2009.igem.org/Team:Brown/Project_HBP"><img src="https://static.igem.org/mediawiki/2009/7/70/Hbpbutton.gif" alt="" width="335" height="100"></td>
 +
    <td colspan="3">&nbsp;<i>EV131 is a high-affinity histamine binding protein, that originates from the saliva of a &nbsp;female tick species.</i> </td>
 +
  </tr>
 +
      <td colspan="2"><a href="https://2009.igem.org/Team:Brown/Project_S.epidermidis"><img src="https://static.igem.org/mediawiki/2009/3/3c/S.epibutton.gif" alt="" width="335" height="100"></td>
 +
    <td colspan="3">&nbsp;<i>The chassis of choice  for production and secretion of the Histamine Binding Protein is &nbsp;Staphyloccocus Epidermidis, an organism endogenous to the human nasal flora. A quorum &nbsp;sensing mechanism was also incorporated to regulate cell density.</i>  </td>
 +
  </tr>
 +
<tr>
 +
    <td colspan="2"><a href="https://2009.igem.org/Team:Brown/Project_All_Together"><img src="https://static.igem.org/mediawiki/2009/1/12/Alltogetherbutton.gif" alt="All Together" width="335" height="100"></a></td>
 +
    <td colspan="3">&nbsp;<i>What happens when an allergy attacks: Description of the overall construct mechanism in &nbsp;S.epidermidis incorporating the histamine sensor, intracellular signal cascade, and &nbsp;transcription of EV131 ligated to secretion peptide.  </i> </td>
 +
  </tr>
 +
</table>
 +
</div>
 +
</font>
 +
</center>
 +
</body></html>
 +
 
 +
----
 +
 
 +
                     
 +
                    '''A special thank you to Team Heidelberg for inspiring our wiki design!'''

Latest revision as of 03:07, 22 October 2009




Brownbanner.gif


Every year, over fifty million people in the US suffer from allergic rhinitis, the most common type of allergy. Allergens such as pollen, dust, and dander result in nasal congestion, itching, burning, sneezing, and overall discomfort. Current treatments include over-the-counter antihistamines, however, side effects of these drugs include drowsiness, restlessness, and poor concentration. For patients suffering from chronic allergies and inflammation, there is a great need for an alternative strategy for combating allergic symptoms without causing significant side effects.


The 2009 Brown University iGEM team worked to treat allergic rhinitis by engineering Staphylococcus epidermidis, a microbe endogenous to the human nasal flora, to secrete a recombinant histamine-binding protein in response to the elevated histamine concentrations of an allergic response. The engineered strain of S. epidermidis will function as a self-regulating drug factory in the nose, providing relief, without any negative side effects.



 Learn more about Allergene: a synthetically engineered, self-regulating drug factory in the  nose.
 When an allergic response occurs, our system senses a change in histamine levels above  threshold and initiates an intracellular cascade, signaling cells to respond appropriately to  the increase in histamine concentration.
 EV131 is a high-affinity histamine binding protein, that originates from the saliva of a  female tick species.
 The chassis of choice for production and secretion of the Histamine Binding Protein is  Staphyloccocus Epidermidis, an organism endogenous to the human nasal flora. A quorum  sensing mechanism was also incorporated to regulate cell density.
All Together  What happens when an allergy attacks: Description of the overall construct mechanism in  S.epidermidis incorporating the histamine sensor, intracellular signal cascade, and  transcription of EV131 ligated to secretion peptide.



                    A special thank you to Team Heidelberg for inspiring our wiki design!